Close Menu

NEW YORK, Oct. 16 – German biotech company atugen and AstraZeneca plan to use atugen’s GeneBloc technology to enhance target validation and drug development in an undisclosed number of “major disease areas” of interest to AstraZeneca.

Terms of the deal call for Berlin-based atugen to retain all rights to specific GeneBlocs it develops for the drugs giant and will have an option to license certain intellectual property generated in the collaboration, according to a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.